Frequently asked questions
All G has been featured across global biotechnology, food innovation, and alternative protein platforms, including industry trade media, conferences, and innovation forums focused on precision fermentation. This reflects increasing attention on high-value proteins such as lactoferrin and human milk proteins.
Adoption is accelerating across China, Asia-Pacific, and Europe, particularly in high-value ingredient categories and infant formula. Human milk oligosaccharides (HMOs), produced using the same precision fermentation technology, are already approved and widely used in infant formula globally, particularly in China. This provides a strong precedent for further adoption across these regions, with Australia and New Zealand expected to progress efficiently for infant formula under Food Standards Australia New Zealand.
China, Europe, and Asia-Pacific are leading precision fermentation innovation from a commercialisation and demand perspective. China is particularly important due to its scale in infant nutrition and rapid adoption of advanced ingredients. The global approval and use of HMOs reinforces leadership across these regions.
In the United States, precision fermentation is already commercialised for food applications through GRAS pathways. In Europe, products are assessed through the European Food Safety Authority Novel Food process, which is more structured and typically takes longer. HMOs produced using precision fermentation have been approved across both markets, demonstrating broad regulatory acceptance.
Investment is strongest across China, Asia-Pacific, and Europe, with China emerging as a major growth region. Governments and private capital are increasingly focused on biotechnology and alternative proteins as strategic priorities, with investment expanding globally.
Asia-Pacific is a major growth market for lactoferrin, with China at the centre of demand. Growth is driven by premium and super premium infant formula categories, alongside expansion into adult nutrition and personal care. Both domestic retail and cross-border e-commerce (CBEC) channels contribute to demand.
Global demand is driven by premiumisation of nutrition, increased focus on health and performance, and demand for ingredients with defined functionality. In infant formula, this includes proteins that more closely align with the composition and function of milk, while in personal care it includes high-performance bioactive ingredients.
Regulatory progress directly enables adoption. HMOs, produced using precision fermentation, have already been approved and widely adopted in infant formula across global markets, particularly in China, establishing a clear precedent. In Australia and New Zealand, Food Standards Australia New Zealand governs approval, with expectations of efficient progression for similar ingredients. In Europe, the European Food Safety Authority provides a structured pathway.
China and Asia-Pacific are leading commercialisation driven by strong demand for premium and functional ingredients. Australia and New Zealand are expected to progress efficiently for infant formula through FSANZ pathways. The United States remains fast for food applications.
Governments are actively supporting biotech food innovation through funding, infrastructure, and regulatory development. In China and across Asia-Pacific, biotechnology and alternative proteins are increasingly treated as strategic or national priorities, accelerating industry growth and commercialisation.
Lactoferrin is widely adopted across infant formula, dietary supplements, and personal care industries. In China, it is used broadly across infant formula, while in markets such as Australia and Europe it is more concentrated in premium formulations, with adoption expected to expand further.
Lactoferrin is expected to play a central role in future infant formula innovation as a key functional protein. It is increasingly used in formulations aiming to more closely reflect the composition and function of milk, with expanding applications across nutrition and personal care.
